Aquavit Pharmaceuticals, Inc. is focused on advancing personalized healthcare through innovative delivery systems, particularly in the fields of neuroscience, medical aesthetics, dermatology, oncology, and immunology. One of their key technologies is the AQUAGOLD® microchannel technology, which allows for the precise delivery of therapeutic agents directly to the skin, enabling healthcare professionals to tailor treatments based on individual patient needs. This technology is complemented by a range of products, including DTX-021, an injectable neuromodulator derived from botulinum toxin, which has demonstrated effectiveness in treating cosmetic concerns such as glabellar lines and periorbital rhytids.

Additionally, Aquavit is developing several other products that leverage their patented microchannel technology. For instance, AQUABELO™ utilizes freeze-dried Hyaluronic Acid for targeted intradermal delivery, while the APOLLO platform integrates smart desktop compounding technology with artificial intelligence and big data capabilities. Other products in their pipeline, such as Microtox™ and iMicrotox™, are designed for low-dose delivery of botulinum toxin, pending FDA clearance. Overall, Aquavit Pharmaceuticals is committed to revolutionizing treatment options through its advanced technologies and personalized medicine approach.

United States

Aquavit Pharmaceuticals, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. 

We focus on personalized medicine to improve patient health and to maximize the efficiency of the medical community. At Aquavit Pharmaceuticals, Inc., we combine this strategic focus with a modern, diverse approach that enables us to pursue new specialty areas with significant unmet needs. 

Science personalized.  Healthcare modernized.

Aquavit Pharmaceuticals, Inc

Company Details